5UK Prospective Diabetes Study(UKPDS)Group.Intensiveblood-glucose control with sulphonylureas or insulin comparedwith conventional treatment and risk of complications in pa-tients with type 2diabetes(UKPDS 33).Lancet,1998,352:837-853.
6Boulton D,Tang A,Patel C,et al.Pharmacokinetics of thedipeptidyl peptidase-4inhibitor saxagliptin in subjects with re-nal impairment.Endo Abstr,2009,20:357.
7Rosenstock J,Sankoh S,List JF.Glucose-lowering activity ofthe dipeptidyl peptidase-4inhibitor saxagliptin in drug-navepatients with type 2diabetes.Diabetes Obes Metab,2008,10:376-386.
8Rosenstock J,Aguilar-Salinas C,Klein E,et al.Effect of saxa-gliptin monotherapy in treatment-naive patients with type 2di-abetes.Curr Med Res Opin,2009,25:2401-2411.
9Defronzo RA,Hissa MN,Garber AJ,et al.The efficacy andsafety of saxagliptin when added to metformin therapy in pa-tients with inadequately controlled type 2diabetes with met-formin alone.Diabetes Care,2009,32:1649-1655.
10Gke B,Gallwitz B,Eriksson J,et al.Saxagliptin is non-infe-rior to glipizide in patients with type 2diabetes mellitus inade-quately controlled on metformin alone:a 52-week randomisedcontrolled trial.Int J Clin Pract,2010,64:1619-1631.
